[Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823].
OBJECTIVE
To determine the effect of a selective COX-2 inhibitor celecoxib on cell proliferation and apoptosis of gastric cancer cell line BGC-823 to seek an effective and safe drug for gastric cancer chemoprevention.


METHODS
Gastric cancer cell line BGC-823 was cultured to 80% fusion. MTT assay and flow cytometry were used to quantify the influence of celecoxib in the proliferation, cell period, and apoptosis of gastric cancer cell line BGC-823. The expression of p21 and Fas by RT-PCR were investigated on gastric cancer cell line BGC-823 by the effect of different celecoxib concentrations.


RESULTS
Growth of BGC-823 cells was inhibited by celecoxib in a dose-and time-dependent manner (P<0.05).Flow cytometry showed that celecoxib increased the proportion of cells in G1 phase, whereas decreased the proportion of cells in S phase and increased the apoptotic rates of cells in a concentration-dependent manner from 0 to 100 micromol/L in gastric cancer cell line BGC-823 (P<0.05). RT-PCR detection showed that the treated BGC-823 cells had increased the expression of p21 and Fas, which was also in a dose-dependent manner (P<0.05).


CONCLUSIONS
Celecoxib inhibited cell proliferation and apoptosis of human gastric cancer cell line BGC-823, which may be related to blocking the cell cycle progress by increasing the expression of p21 and inducing the apoptosis of gastric cancer cells by increasing the expression of Fas.
Li
Qian
Q
Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, China. liqian0816@sina.com
Peng
Jie
J
Zhang
Gui-Ying
GY
D017209:Apoptosis / Q000187:drug effects*; D000068579:Celecoxib; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D011720:Pyrazoles / Q000494:pharmacology*; D013274:Stomach Neoplasms / Q000473:pathology*; D013449:Sulfonamides / Q000494:pharmacology*; D019014:fas Receptor / Q000378:metabolism
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D052246:Cyclooxygenase 2 Inhibitors; C491901:FAS protein, human; D011720:Pyrazoles; D013449:Sulfonamides; D019014:fas Receptor; D000068579:Celecoxib